24/7 Market News Snapshot 20 October, 2025 – IO Biotech, Inc. Common Stock (NASDAQ:IOBT)

October 20, 2025

DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (Nasdaq:IOBT) are discussed in this article.
IO Biotech, Inc. (Nasdaq:IOBT) has recently captured attention in the financial markets, with its stock price soaring to $0.837, marking a 27.75% increase from the previous close of $0.655 during pre-market trading. This surge comes amidst significant trading volumes, approaching 6.98 million shares, reflecting heightened investor enthusiasm and interest in the company’s innovative developments. Technical indicators suggest that this upward trend may persist, as IOBT has successfully breached key resistance levels, enticing investors to closely monitor the stock for potential further gains.

Simultaneously, IO Biotech is making headlines in the scientific community with the presentation of promising results from its investigational therapy, Cylembio®, at the European Society for Medical Oncology (ESMO) Congress 2025. The global Phase 3 trial, IOB-013/KN-D18, demonstrated the effectiveness of Cylembio® when administered alongside Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients diagnosed with unresectable or metastatic melanoma. The combination therapy achieved a median progression-free survival (mPFS) of 19.4 months, a significant improvement compared to the 11.0 months mPFS recorded for those receiving pembrolizumab alone. While the study did not meet the predefined statistical significance threshold, the combination showcased consistent superiority across diverse clinical subgroups, especially in patients harboring PD-L1-negative tumors and those with BRAFV600 mutations.

Dr. Mai-Britt Zocca, President and CEO of IO Biotech, emphasized the potential of Cylembio® as a transformative treatment option across various cancer types, highlighting its robust safety profile revealed in concurrent Phase 2 trials. As IO Biotech continues to push boundaries in the biotech landscape, the company’s commitment to enhancing patient outcomes in the face of challenging cancers solidifies its position as a noteworthy player in the industry.

Related news for (IOBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.